Annual General Meeting on April 29, 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

BioEurope Spring – virtual

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

Cell & Gene Meeting on the Mediterranean, virtual

4th Annual Gene Therapy for Rare Disorders – virtual

OIS Gene Therapy Innovation Showcase – virtual

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar